Radiation therapy in the locoregional treatment of triple-negative breast cancer.
This Review assesses the relevant data and controversies regarding the use of radiotherapy for, and locoregional management of, women with triple-negative breast cancer (TNBC). In view of the strong association between BRCA1 and TNBC, knowledge of baseline mutation status can be useful to guide locoregional treatment decisions. TNBC is not a contraindication for breast conservation therapy because data suggest increased locoregional recurrence risks (relative to luminal subtypes) with breast conservation therapy or mastectomy. Although a boost to the tumour bed should routinely be considered after whole breast radiation therapy, TNBC should not be the sole indication for post-mastectomy radiation, and accelerated delivery methods for TNBC should be offered on clinical trials. Preliminary data implying a relative radioresistance for TNBC do not imply radiation omission because radiation provides an absolute locoregional risk reduction. At present, the integration of subtypes in locoregional management decisions is still in its infancy. Until level 1 data supporting treatment decisions based on subtypes are available, standard locoregional management principles should be adhered to.
Yale University School of Medicine, Department of Therapeutic Radiology, New Haven, CT, USA. Electronic address: Meena.Moran@yale.edu.
Meena S
MS
Moran
D014408:Biomarkers, Tumor / Q000032:analysis / Q000235:genetics; D003661:Decision Support Techniques; D019583:Dose Fractionation, Radiation; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D008408:Mastectomy; D009364:Neoplasm Recurrence, Local; D018579:Patient Selection; D010641:Phenotype; D011237:Predictive Value of Tests; D011836:Radiation Tolerance; D018714:Radiotherapy, Adjuvant; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome; D064726:Triple Negative Breast Neoplasms / Q000737:chemistry / Q000235:genetics / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery*
D014408:Biomarkers, Tumor